Umbilical Cord Blood Derived MAK Immune Cells Combined With Standard Second-Line Treatments for Hepatobiliary and Pancreatic Malignancies
To evaluate the safety of MAK immune cells derived from umbilical cord blood combined with second-line treatments for hepatobiliary and pancreatic malignancies.And to investigate the initial efficacy of MAK immune cells derived from umbilical cord blood combined with second-line treatments for hepatobiliary and pancreatic malignancies.
Stage IV Pancreatic Cancer|Hepatocellular Carcinoma , Cholangiocarcinoma
BIOLOGICAL: Umbilical Cord Blood Derived MAK Immune Cells
Progression-free Survival(PFS), PFS is defined as the time from enrollment to the first documented disea, 24 months
overall survival (OS), OS is the time from enrollment to death due to any cause., 24 months|objective response rate (ORR), and partial response (PR) by the investigator according to the RECIST 1.1., 24 months|disease control rate (DCR), DCR was defined as the percentage of participants who have a confirmed complete response（CR） or partial response（PR） or stable disease（SD） per RECIST 1.1 as assessed by investigator, 24 months
To evaluate the safety of MAK immune cells derived from umbilical cord blood combined with second-line treatments for hepatobiliary and pancreatic malignancies.And to investigate the initial efficacy of MAK immune cells derived from umbilical cord blood combined with second-line treatments for hepatobiliary and pancreatic malignancies.